Proc Natl Acad Sci USA 2004, 101:16923–16928.CrossRefPubMed 29. Yamaoka Y, Kwon DH, Graham DY: A M(r) 34,000 proinflammatory outer membrane protein (OipA) of Helicobacter pylori. Proc Natl Acad Sci U S A 2000, 97:7533–7538.CrossRefPubMed 30. Hennig EE, Mernaugh R, Edl J, Cao P, Cover TL: Heterogeneity among Helicobacter pylori strains in expression of the outer membrane protein BabA. Infect Immun 2004, 72:3429–3435.CrossRefPubMed 31. Pride DT, Blaser MJ: Concerted evolution between duplicated genetic elements in Helicobacter

pylori. J Mol Biol 2002, 316:629–642.CrossRefPubMed 32. Santoyo G, Romero D: Gene conversion and concerted evolution in bacterial genomes. FEMS Microbiol Lett 2005, 29:169–183. 33. Pride MK-4827 research buy DT, Meinersmann RJ, Blaser MJ: Allelic variation within Helicobacter pylori babA and babB. Infect Immun 2001, 69:1160–1171.CrossRefPubMed 34. Cao P, Cover TL: Two different families of hopQ alleles in Helicobacter pylori. J Clin Microbiol buy CB-5083 2002,

40:4504–4511.CrossRefPubMed 35. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series 1999, 41:95–98. 36. Rice P, Longden I, Bleasby A: EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 2000, 16:276–277.CrossRefPubMed 37. Kumar S, Tamura K, Nei M: MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 2004, 5:150–163.CrossRefPubMed 38. Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol

1980, 16:111–120.CrossRefPubMed 39. Nei M, Gojobori T: Simple methods for estimating the numbers of Thalidomide synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986, 3:418–426.PubMed 40. Nei M, Kumar S: Synonymous substitutions and non synonymous nucleotide substitutions. Molecular Evolution and Phylogenetics (Edited by: Nei M). New York: Oxford University Press 2000, 1:52–61. Authors’ contributions MO carried out experimental TGF-beta/Smad inhibitor design of the study, phylogenetic analysis and co-drafted the manuscript; RC carried out bacterial cultures, PCR and phylogenetic analysis; AM co-drafted the manuscript; YY and DQ carried out bacterial cultures and PCR; FM and LM supervised the study. All authors have read and approved the final version of the manuscript.”
“Background Over the past 30 years, the search for bioactive secondary metabolites (natural products) from marine organisms has yielded a wealth of new molecules (estimated at ~17,000) with many fundamentally new chemotypes and extraordinary potential for biomedical research and applications [[1], and previous references therein]. Marine cyanobacteria continue to be among the most fruitful sources of marine natural products, with nearly 700 compounds described [2, 3].